News
HBV, HCV, HIV testing of new cancer patients advised
Many patients with newly diagnosed cancers were unaware of their infection status, and some had no known risk factors.
News
AML, myeloma risk higher for breast cancer survivors
Risk for both myeloid and lymphoid neoplasms was higher among breast cancer survivors than in the general population.
News
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
News
Long-term side effects of CAR T cells mostly mild
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
News
Lenalidomide maintenance improves MCL survival after ASCT
SAN DIEGO – PFS was better post transplant with lenalidomide maintenance, but it’s too early to know whether OS will be improved.
News
Quizartinib improves survival of FLT3-mutated AML
SAN DIEGO – QuANTUM-R is the first randomized trial to show a survival benefit over salvage chemotherapy in patients with FLT3-ITD mutated AML.
News
DRd improves PFS in transplant-ineligible MM
SAN DIEGO—An interim analysis from the MAIA trial showed that adding daratumumab to lenalidomide and dexamethasone could significantly improve...
News
Risk of second cancers in Hodgkin lymphoma survivors
Survivors of childhood Hodgkin lymphoma (HL) have a 14-fold higher risk of second cancers compared to the general population, according to new...
News
Lack of gut diversity hurts survival after HCT
SAN DIEGO – Patients with low diversity of intestinal microflora have worse overall survival after hematopoietic cell transplant.
News
Survivors of childhood Hodgkin lymphoma face 14-fold risk of second cancers
The findings highlight the need to screen high-risk subgroups of cancer survivors.
News
Adjuvant modified FOLFIRINOX improves survival of pancreatic cancer
Disease-free and overall survival were significantly higher with modified FOLFIRINOX vs. gemcitabine, the current standard of care.
News
Sorafenib extends PFS for refractory desmoid tumors
The oral tyrosine kinase inhibitor was associated with durable responses and a high progression-free survival rate in patients with refractory or...
News
Frontline veliparib/cisplatin/etoposide shows efficacy in advanced SCLC
Adding the PARP inhibitor to standard frontline chemotherapy offered a slight PFS benefit but no overall survival benefit.
News
Low BMP-10 levels correlate with poor ovarian cancer survival
Studies of ovarian cancer tissues and cell lines suggest that bone morphogenetic protein-10 (BMP-10) may be a tumor suppressor.
Video
MAIA: Daratumumab plus len-dex improves myeloma PFS
SAN DIEGO – Adding the anti-CD38 monoclonal antibody to lenalidomide and dexamethasone significantly decreased 30-month risk of progression.